Spero Therapeutics Inc
SPRO2.500USD
+0.370+17.37%
收盘 05/30, 16:00（美东）报价延迟15分钟
139.75M总市值
亏损市盈率 TTM
关于 Spero Therapeutics Inc 公司
Spero Therapeutics, Inc. 是一家临床阶段的生物制药公司。该公司专注于识别和开发罕见病和多重耐药 (MDR) 细菌感染的新疗法，这些疗法尚未得到满足。其主要候选产品 SPR720 是一种口服抗菌剂，用于治疗一种罕见的孤儿病——非结核分枝杆菌 (NTM) 肺病。其合作伙伴指导的项目包括替比培南 HBr 和 SPR206。替比培南 HBr 旨在成为口服卡巴培南类抗生素，用于治疗某些细菌感染，这些细菌感染会导致由某些微生物引起的复杂性尿路感染 (cUTI)，包括肾盂肾炎，这些细菌感染适用于口服治疗选择有限的成年患者。SPR206 是一种直接作用的静脉 (IV) 给药候选产品，正在开发中，作为在医院环境中治疗 MDR 革兰氏阴性细菌感染的一种选择。
公司简介
公司代码SPRO
公司名称Spero Therapeutics Inc
上市日期Nov 02, 2017
成立日期2013
CEOMs. Esther Rajavelu
员工数量32
证券类型Ordinary Share
年结日Nov 02
公司地址675 Massachusetts Ave Ste 14
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02139-3309
电话18572421600
网址https://sperotherapeutics.com/
公司代码SPRO
上市日期Nov 02, 2017
成立日期2013
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
350.79K
+112.94%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
228.68K
+423.52%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
147.00K
-45.80%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
+38.87%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
55.00K
+57.14%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
+57.14%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
55.00K
+57.14%
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
Dr. Patrick Volkert Jo Vink, M.D.
Dr. Patrick Volkert Jo Vink, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. John C. Pottage, Jr., M.D.
Dr. John C. Pottage, Jr., M.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
350.79K
+112.94%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
228.68K
+423.52%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
147.00K
-45.80%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
+38.87%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
55.00K
+57.14%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
+57.14%
收入明细
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
暂无数据
地区USD
名称
营收
占比
United States
47.98M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
股东统计
占比
GSK plc
16.44%
Anson Funds Management LP.
6.79%
Pfizer Inc
4.23%
The Vanguard Group, Inc.
3.15%
Renaissance Technologies LLC
1.74%
Other
67.65%
持股股东
股东统计
占比
GSK plc
16.44%
Anson Funds Management LP.
6.79%
Pfizer Inc
4.23%
The Vanguard Group, Inc.
3.15%
Renaissance Technologies LLC
1.74%
Other
67.65%
股东类型
股东统计
占比
Corporation
20.66%
Hedge Fund
10.30%
Investment Advisor/Hedge Fund
8.22%
Individual Investor
3.66%
Venture Capital
2.58%
Investment Advisor
2.01%
Research Firm
0.14%
Other
52.43%
机构持股
更新时间: 3月4日 周二
更新时间: 3月4日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q1
114
27.91M
50.02%
+3.00M
2024Q4
125
27.51M
50.50%
+2.91M
2024Q3
143
24.19M
44.62%
-8.19M
2024Q2
160
25.74M
47.53%
-7.31M
2024Q1
203
25.36M
47.08%
-8.60M
2023Q4
209
24.88M
47.35%
-1.62M
2023Q3
223
24.62M
47.01%
-2.06M
2023Q2
230
24.99M
47.83%
-1.96M
2023Q1
242
24.74M
47.38%
-2.46M
2022Q4
247
26.52M
54.04%
-1.18M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
GSK plc
9.19M
16.44%
--
--
Mar 27, 2025
Anson Funds Management LP.
3.84M
6.87%
+89.44K
+2.38%
Dec 31, 2024
Pfizer Inc
2.36M
4.23%
+2.36M
--
Dec 31, 2024
The Vanguard Group, Inc.
1.76M
3.15%
--
--
Dec 31, 2024
Renaissance Technologies LLC
1.11M
1.98%
+130.94K
+13.43%
Dec 31, 2024
Alphabet, Inc.
889.98K
1.59%
--
--
Dec 31, 2024
Murchinson Ltd.
873.91K
1.56%
+873.91K
--
Dec 31, 2024
Acadian Asset Management LLC
1.04M
1.86%
-31.94K
-2.98%
Dec 31, 2024
Adar1 Capital Management LLC
801.28K
1.43%
+57.82K
+7.78%
Dec 31, 2024
Hamed (Kamal)
788.12K
1.41%
+211.66K
+36.72%
Feb 02, 2024
查看更多
持股ETF
更新时间: 5月6日 周二
更新时间: 5月6日 周二
机构名称
占比
iShares Micro-Cap ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
Avantis US Small Cap Equity ETF
0%
Royce Quant Small-Cap Quality Value ETF
0%
iShares Micro-Cap ETF
占比0.01%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
Royce Quant Small-Cap Quality Value ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
